1.    PRODUCT OVERVIEW

1.1.  MARKET DEFINITION

1.2.  SCOPE OF THE MARKET

1.2.1.    MARKETS COVERED

1.2.2.    YEARS CONSIDERED FOR STUDY

1.2.3.    KEY MARKET SEGMENTATIONS

2.    RESEARCH METHODOLOGY

2.1.  OBJECTIVE OF THE STUDY

2.2.  BASELINE METHODOLOGY

2.3.  KEY INDUSTRY PARTNERS

2.4.  MAJOR ASSOCIATION AND SECONDARY SOURCES

2.5.  FORECASTING METHODOLOGY

2.6.  DATA TRIANGULATION & VALIDATION

2.7.  ASSUMPTIONS AND LIMITATIONS

3.    EXECUTIVE SUMMARY

3.1.  OVERVIEW OF THE MARKET

3.2.  OVERVIEW OF KEY MARKET SEGMENTATIONS

3.3.  OVERVIEW OF KEY MARKET PLAYERS

3.4.  OVERVIEW OF KEY REGIONS/COUNTRIES

3.5.  OVERVIEW OF MARKET DRIVERS, CHALLENGES, TRENDS

4.    VOICE OF CUSTOMER

5.     JAPAN HERPES SIMPLEX VIRUS THERAPEUTICS MARKET OUTLOOK

5.1.  MARKET SIZE & FORECAST

5.1.1.    BY VALUE

5.2.  MARKET SHARE & FORECAST

5.2.1.    BY TREATMENT (ANTIVIRAL MEDICATIONS- ACYCLOVIR, VALACYCLOVIR, FAMCICLOVIR, PRITELIVIR, SUPPRESSIVE THERAPY, EPISODIC THERAPY, TOPICAL TREATMENTS, GENE EDITING TECHNOLOGIES, THERAPEUTIC VACCINES, NANOPARTICLE-BASED DELIVERY SYSTEMS, IMMUNE MODULATORS) 

5.2.2.    BY TYPE (TYPE I, TYPE II)

5.2.3.    BY PATIENT AGE (NEONATE, ADULT)

5.2.4.    BY DISTRIBUTION CHANNEL (HOSPITAL, CLINICS, PHARMACY)

5.2.6.    BY REGION

5.2.7.    BY COMPANY (2024)

5.3.  MARKET MAP

6.    HOKKAIDO HERPES SIMPLEX VIRUS THERAPEUTICS MARKET OUTLOOK

6.1.  MARKET SIZE & FORECAST

6.1.1.    BY VALUE

6.2.  MARKET SHARE & FORECAST

6.2.1.    BY PRODUCT

6.2.2.    BY DISTRIBUTION CHANNEL

7.    TOHOKU HERPES SIMPLEX VIRUS THERAPEUTICS MARKET OUTLOOK

7.1.  MARKET SIZE & FORECAST

7.1.1.    BY VALUE

7.2.  MARKET SHARE & FORECAST

7.2.1.    BY PRODUCT

7.2.2.    BY DISTRIBUTION CHANNEL

8.    KANTO HERPES SIMPLEX VIRUS THERAPEUTICS MARKET OUTLOOK

8.1.  MARKET SIZE & FORECAST

8.1.1.    BY VALUE

8.2.  MARKET SHARE & FORECAST

8.2.1.    BY PRODUCT

8.2.2.    BY DISTRIBUTION CHANNEL

9.    CHUBU HERPES SIMPLEX VIRUS THERAPEUTICS MARKET OUTLOOK

9.1.  MARKET SIZE & FORECAST

9.1.1.    BY VALUE

9.2.  MARKET SHARE & FORECAST

9.2.1.    BY PRODUCT

9.2.2.    BY DISTRIBUTION CHANNEL

10. KANSAI HERPES SIMPLEX VIRUS THERAPEUTICS MARKET OUTLOOK

10.1.   MARKET SIZE & FORECAST        

10.1.1. BY VALUE

10.2.   MARKET SHARE & FORECAST

10.2.1. BY PRODUCT

10.2.2. BY DISTRIBUTION CHANNEL

11. CHUGOKU HERPES SIMPLEX VIRUS THERAPEUTICS MARKET OUTLOOK

11.1.   MARKET SIZE & FORECAST        

11.1.1. BY VALUE

11.2.   MARKET SHARE & FORECAST

11.2.1. BY PRODUCT

11.2.2. BY DISTRIBUTION CHANNEL

12. SHIKOKU HERPES SIMPLEX VIRUS THERAPEUTICS MARKET OUTLOOK

12.1.   MARKET SIZE & FORECAST        

12.1.1. BY VALUE

12.2.   MARKET SHARE & FORECAST

12.2.1. BY PRODUCT

12.2.2. BY DISTRIBUTION CHANNEL

13. KYUSHU HERPES SIMPLEX VIRUS THERAPEUTICS MARKET OUTLOOK

13.1.   MARKET SIZE & FORECAST        

13.1.1. BY VALUE

13.2.   MARKET SHARE & FORECAST

13.2.1. BY PRODUCT

13.2.2. BY DISTRIBUTION CHANNEL

14. MARKET DYNAMICS

14.1.   DRIVERS

14.2.   CHALLENGES

15. MARKET TRENDS & DEVELOPMENTS

15.1.   RECENT DEVELOPMENTS

15.2.   PRODUCT LAUNCHES

15.3.   MERGERS & ACQUISITIONS

16.  JAPAN HERPES SIMPLEX VIRUS THERAPEUTICS MARKET: SWOT ANALYSIS

17. COMPETITIVE LANDSCAPE

17.1.   GILEAD SCIENCES

17.1.1.       BUSINESS OVERVIEW

17.1.2.       PRODUCT & SERVICE OFFERINGS

17.1.3.       RECENT DEVELOPMENTS

17.1.4.       KEY PERSONNEL

17.1.5.       FINANCIALS (IF LISTED)

17.1.6.       SWOT ANALYSIS

17.2.   PFIZER

17.3.   SANOFI

17.4.   NOVARTIS

17.5.   ABBVIE.

17.6.   JOHNSON & JOHNSON

17.7.   CELGENE

17.8.   ASTRAZENECA MERCK & CO.

18. STRATEGIC RECOMMENDATIONS

19. ABOUT US & DISCLAIMER